P. Podrid

Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: Results from the thrombolysis in myocardial infarction (TIMI) phaes II trial

T. Ryan, P. Berger, N. Ruocco, 1993 .

Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction.

R. Pedretti, R. Tramarin, P. J. Podrid, 1998, Journal of the American College of Cardiology.

Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial.

T. Ryan, P. Berger, P. J. Podrid, 1993, Journal of the American College of Cardiology.

Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia--a status report, 1987.

L. Horowitz, J. Bigger, M. Rosen, 1987, The American journal of cardiology.

Therapeutic and Diagnostic Benefits of Intentional Crosstalk Mediated Ventricular Output Inhibition

P. Levine, F. Venditti, P. Podrid, 1988, Pacing and clinical electrophysiology : PACE.

Right coronary artery stenosis: an independent predictor of atrial fibrillation after coronary artery bypass surgery.

T. Ryan, L. Cupples, R. Shemin, 1995, Journal of the American College of Cardiology.

Efficacy and safety of moricizine in patients with congestive heart failure: a summary of the experience in the United States.

C. Pratt, P. Podrid, S. Mahler, 1990, American heart journal.